In autopsy findings from donated brains, inflammation was present in most individuals and was associated with clinical outcomes.
The relative contributions of inflammation and neurodegeneration in progressive multiple sclerosis (MS) remain unknown. Slowly expanding lesions and paramagnetic rim lesions suggest ongoing inflammation not entirely treated by current therapies (NEJM JW Neurol Oct 15 2019 and Brain 2019; 142:2787; NEJM JW Neurol July 24 2023 and Ann Neurol 2023; 84:736). To clarify the extent of inflammation late in MS, investigators evaluated 269 donated postmortem brains from patients with progressive MS for evidence of late inflammation.
High-grade perivenular inflammation (PVI) was present in 52%, and at least one active lesion was present in 22%. PVI was associated with active lesions, earlier age of MS, shorter times of progression to wheelchair and to…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)